Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
This article was originally published in The Gray Sheet
Executive Summary
CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations
You may also be interested in...
Electronic Standards Key To Better Demographic Data In Trials – McClellan
Electronic clinical trial databases under development at the FDA Office of Women's Health will help sponsors design trials that account for gender and other demographic differences among patients, according to Commissioner Mark McClellan
Electronic Standards Key To Better Demographic Data In Trials – McClellan
Electronic clinical trial databases under development at the FDA Office of Women's Health will help sponsors design trials that account for gender and other demographic differences among patients, according to Commissioner Mark McClellan
Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC
Coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have age-related macular degeneration and occult lesions with no classic choroidal neovascularization (CNV) should be restricted to those with small lesions, according to several MCAC panel members